© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
A panel discussion focused on advances in the management of treatment-resistant depression and the fundamentals of certified treatment centers for the dispensing and administration of esketamine.
May 6th 2021
Dr Angelos Halaris provides clarity to the definition of treatment-resistant depression and suggests what may contribute to high prevalence rates.
The rationale for treating treatment-resistant depression and other psychiatric conditions with off-label intravenous ketamine.
An overview of what is currently recommended by the APA guidelines for the management of treatment-resistant depression, with insight regarding topics that need to be revisited and addressed further to help standardize care for patients.
May 13th 2021
A description regarding the mechanism of action of intranasal esketamine, a newer therapy for treatment-resistant depression, and current opportunities for use over other treatment options.
Criteria that can be used to help determine who may or may not be appropriate for intranasal esketamine therapy for treatment-resistant depression.
Strategies that can be used to monitor patients on intranasal esketamine therapy for treatment-resistant depression, with special considerations surrounding blood pressure management.
May 20th 2021
Practical experience regarding the timing and response to intranasal esketamine therapy for treatment-resistant depression.
The purpose and impact of the REMS program established to support the integration of intranasal esketamine into clinics that manage treatment-resistant depression.
Best practices that can be applied when working with patients and training staff on proper ways to administer intranasal esketamine therapy for treatment-resistant depression in a supervised medical setting.
Requirements that healthcare clinics must satisfy to become a certified treatment center permitted to administer intranasal esketamine to patients with treatment-resistant depression.